



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

August 6, 2014

**Location: Learning Resource Center  
Community Room  
3550 Mills Civic Parkway  
West Des Moines, Iowa**

**Time: 9:30 a.m. – 1:30 p.m.**

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
  - b) Approval of the Minutes
2. Commission Business
  - a) Annual Completion of Conflict of Interest Disclosure
  - b) Annual DUR Commission Chairperson and Vice Chairperson Elections
  - c) DHS Recommendation Letter – June 2014
  - d) Article of Interest - MMWR/Vol. 63/No.26 – *Variation Among States in Prescribing of Opioid Pain Relievers and Benzodiazepines – United States, 2013* <http://www.cdc.gov/mmwr/pdf/wk/mm6326.pdf>
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
  - a) Emergency Contraception – Follow Up
  - b) Albuterol MDI Over Utilization –Follow Up
  - c) Albuterol MDI Over Utilization without Inhaled Corticosteroid – Follow Up
  - d) Long Term Use of Short-Acting Opioids – Updated
  - e) Prasugrel Contraindications – Initial Review
  - f) Duplicate Antipsychotics – Initial Review
  - g) Eszopiclone Dose – Initial Review

8. Public Comment (See Conflict of Interest Disclosure Form)
9. Prior Authorization
  - a) Chronic Pain Syndromes – Initial Review – Updated
  - b) Naloxone (Evzio™) – Initial Review
  - c) Oral Immunotherapy – Initial Review
  - d) Methotrexate Injection – Initial Review
  - e) Tasimelteon (Helitoz™) – Initial Review
  - f) Apremilast (Otezla®) – Initial Review
  - g) Palivizumab (Synagis®) – Initial Review
  - h) Vorapaxar (Zontivity™) – Initial Review
  - i) Omalizumab (Xolair®) – Second Review
  - j) Apixaban (Eliquis®) – Second Review
  - k) Dabigatran (Pradaxa®) – Second Review
10. Neuraminidase Inhibitor Utilization
11. Miscellaneous
  - a) DUR Digest Vol. 27, No. 1 – Initial Review
  - b) MedWatch
12. Executive Closed Session
  - a) Approval of Minutes
  - b) Member Profiles
13. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

**[www.iadur.org](http://www.iadur.org)**

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting October 1, 2014\*\*\*  
at the West Des Moines Learning Resource Center  
3550 Mills Civic Parkway, West Des Moines**